GlassScriptPhysician profile
John B Kelly
NPI 1043599269
$96,947.96
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $23K · 2021: $21K · 2022: $4,661.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92,840.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $2,913.89 | 2019-2022 | |
| Epi Health, LLC | $270.65 | 2021-2022 | |
| Lilly USA, LLC | $169.06 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $114.44 | 2019 | |
| Janssen Biotech, INC. | $110.63 | 2021 | |
| Sun Pharmaceutical Industries INC. | $100.00 | 2019 | |
| Pfizer INC. | $99.49 | 2019-2022 | |
| Celgene Corporation | $90.63 | 2019 | |
| Amgen INC. | $87.15 | 2020 | |
| Incyte Corporation | $68.35 | 2021 | |
| Leo Pharma INC. | $53.39 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.59 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,528.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.